These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 34663682)
1. Biologics for Asthma and Allergic Skin Diseases in Children. De Keyser HH; Chipps B; Dinakar C; Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34663682 [TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Jackson K; Bahna SL Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421 [No Abstract] [Full Text] [Related]
3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960 [TBL] [Abstract][Full Text] [Related]
4. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database. Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062 [TBL] [Abstract][Full Text] [Related]
5. Biologics in allergic rhinitis. Bayar Muluk N; Cingi C Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947 [TBL] [Abstract][Full Text] [Related]
6. Severe asthma: When to resort to biological agents. Tenero L; Rossignoli S; Piacentini G Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206 [TBL] [Abstract][Full Text] [Related]
7. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951 [TBL] [Abstract][Full Text] [Related]
11. Strategies for choosing a biologic for your patient with allergy or asthma. Saco T; Ugalde IC; Cardet JC; Casale TB Ann Allergy Asthma Immunol; 2021 Dec; 127(6):627-637. PubMed ID: 34642091 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation. L Ramos C; Namazy J Immunol Allergy Clin North Am; 2023 Feb; 43(1):187-197. PubMed ID: 36411004 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of refractory asthma with antibodies]. Lommatzsch M Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629 [TBL] [Abstract][Full Text] [Related]
14. An update on biological therapies for pediatric allergic diseases. Castagnoli R; De Filippo M; Votto M; Marseglia A; Montagna L; Marseglia GL; Licari A Minerva Pediatr; 2020 Oct; 72(5):364-371. PubMed ID: 32686927 [TBL] [Abstract][Full Text] [Related]
15. [Dermatological implications of omalizumab, an anti-IgE antibody]. Di Lucca-Chrisment J Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Chipps BE; Figliomeni M; Spector S Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179 [TBL] [Abstract][Full Text] [Related]
17. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688 [TBL] [Abstract][Full Text] [Related]